Sorrento Therapeutics Inc (SRNE)

[dia76ca]

SIX (6) REASONS 2022 will be PIVOTAL for SORRENTO
1. ABIVERTINIB $61 Billion global market partnership(s). There will be multi-billion upfront, milestone and royalty payments. And look to the partnership partners to become the eventual buyout actors!
2. SCILEX SPINOFF. More SP-102 data is due in January. This new treatment could gross $6-10 billion annually in the US alone!. The partner is a wealthy Singapore based venture capital firm.
3. COVISTIX REVENUE STREAM. Sales have recorded in Q4 of 2021 and will ramp up in Q1 of 2022. Europe, Central and South America, Canada, Japan and the US will follow.
4. COVIDROPS, COVI-MSC, COVISHIELD, SP-102, ABIVERTINIB(cancer and Covid) news is expected in Q1 2022 as are more EUA's. SP-102 and ABIVERTINIB revenue expected in 2H of 2022.
5. ORAL MP18 based PAN-COVID ANTI-VIRAL. A peer-reviewed publication was released showing strong pan-Covid activity (including Omicron). This could enter the clinic in Q1 or Q2. A world-wide development and marketing partner might be expected. Look for something better than Merck or Pfizer's drugs!
6. In Cancer Sorrento has more than 10 fully human antibodies in the clinic or late pre-clinical(PD-1, PD-L1, CD38, CD123, CD47,BCMA, TROP2, LAG3, CTLA-4 and CD137). Allogenic DAR-T and a second generation oncolytic virus(Seprehvec) will enter the clinic as well as several additional ADNAB(Mayo Clinic) drugs.